ANBOGEN THERAPEUTICS
Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients worldwide.
ANBOGEN THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Oncology
Founded:
2019-01-01
Address:
Nankang, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.anbogen.com
Total Employee:
11+
Status:
Active
Contact:
+886 2 8979 8616
Email Addresses:
[email protected]
Total Funding:
19.8 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API WordPress Google Maps Content Delivery Network LetsEncrypt
Similar Organizations
Actym Therapeutics, Inc.
Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Fore Biotherapeutics
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Investors List
KGI Venture Capital
KGI Venture Capital investment in Series A - AnBogen Therapeutics
Maxpro Ventures
Maxpro Ventures investment in Series A - AnBogen Therapeutics
TaiAn Technologies
TaiAn Technologies investment in Series A - AnBogen Therapeutics
China Development Industrial Bank (CDIB)
China Development Industrial Bank (CDIB) investment in Series A - AnBogen Therapeutics
National Development Fund of Taiwan Government
National Development Fund of Taiwan Government investment in Series A - AnBogen Therapeutics
Official Site Inspections
http://www.anbogen.com Semrush global rank: 8.44 M Semrush visits lastest month: 531
- Host name: 172.67.186.228
- IP address: 172.67.186.228
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AnBogen Therapeutics"
Anbogen
Our precision oncology drugs in development exemplify Anbogen's unwavering commitment to addressing unmet medical needs. By leveraging the concept of targeted therapy in precision …See details»
安邦生技-Investors-Corporate Governance - anbogen.com
Organization of internal audit. The internal audit department of this company operates independently and reports directly to the Board of Directors. It includes an internal audit …See details»
安邦生技-Our Vsion - anbogen.com
In August 2022, Anbogen's laboratory, located in the National Biotechnology Research Park, was officially inaugurated. 2022.03. In March 2022, the TFDA approved the phase 1b/2 clinical trial …See details»
AnBogen Therapeutics - Crunchbase Company Profile & Funding
AnBogen Therapeutics may be growing as it has successfully raised $12.5 million in a series A funding round, which is a significant financial milestone for any clinical-stage biotech company. …See details»
AnBogen Therapeutics Company Profile 2024: Valuation, Funding ...
AnBogen Therapeutics was founded in 2019. Where is AnBogen Therapeutics headquartered? AnBogen Therapeutics is headquartered in Taipei, Taiwan. What industry is AnBogen …See details»
AnBogen Therapeutics - LinkedIn
Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge …See details»
AnBogen Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore AnBogen Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 5 news, and 1 literature, Disease Domain:Neoplasms, Technology …See details»
AnBogen Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jul 1, 2024: Series A - …See details»
AnBogen Therapeutics - VentureRadar
Anbogen Therapeutics (ABT) is a clinical-stage company that spun off from the National Health Research Institutes, the most prestigious medical research institute in Taiwan. As the leader in …See details»
AnBogen Therapeutics - Contacts, Employees, Board Members
Anbogen Therapeutics is a clinical-stage biotech company to creating breakthrough science that changes the life of cancer patients. Search Crunchbase Start Free TrialSee details»
安邦生技-Investors-Board of Directors & Committees
Harness the Power of Science to Cure Cancer. Our company selects directors based on their industry expertise, professional domain, and practical experience, ensuring they possess the …See details»
Anbogen Secures 12.5 Million in Series A Funding, Advancing …
TAIPEI, Feb. 1, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the …See details»
Anbogen Secures 12.5 Million in Series A Funding, Advancing
Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients …See details»
Anbogen Secures 12.5 Million in Series A Funding, Advancing …
Jan 31, 2024 Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives …See details»
Taiwan-based startup Anbogen secures $12.5 M for advancing …
Feb 2, 2024 The raised capital will be directed towards the ongoing development of Anbogen's two main drug candidates, ABT-101 and ABT-301. Both of these candidate drugs were …See details»
Anbogen Therapeutics Announces Completion of A+ Round …
Jul 1, 2024 Anbogen Therapeutics, Inc., a clinical-stage company dedicated to developing breakthrough cancer therapies, has announced the successful closing of a USD 7.3M …See details»
安邦生技-Investors-Financial Information - anbogen.com
Financial Statement for the six months ended June 30, 2024 and 2023See details»
Timeline - Anbogen
In October 2020, Anbogen signed a license agreement for ABT-301 with Taipei Medical University. 2022 March. In March 2022, the TFDA approved the phase 1b/2 clinical trial of ABT …See details»
Anbogen Announces Drug Supply Collaboration with BeiGene to …
Sep 27, 2024 Anbogen is a clinical-stage biotech company that completed a US$20M Series A in 2024. We are dedicated to developing precision anti-cancer drugs and are committed to …See details»
安邦生技-Innovation - anbogen.com
ABT-101. ABT-101, is an oral, tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) patients harboring exon 20 insertions (e20i) in HER2, exon20 kinase domain …See details»